Outcome of Rhabdomyosarcoma in First Year of Life: Children’s Cancer Hospital 57357 Egypt

Table 2

High risk protocol roadmap.

Weeks	0	1	2	3	4	5	6	7	8	9	10	11	12
	VAC	V	V	VAC	V	V	VAC	V	V	VAC	V	V	VAC **
Weeks	13	14	15	16	17	18	19	20	21	22	23	24	25
	—	—	VC	—	—	VC	V	V	V	VAC	V	V**	VAC
Weeks	26	27	28	29	30	31	32	33	34	35	36	37	40
	V	V	VAC	—	—	VAC	V	V	VAC	V	V	VAC	**

Vincristine (V): 1.5 mg/m² IV push.
Actinomycin (A): 1.35 mg/m² IV push.
Cyclophosphamide (C): 1.5 mg/m² at weeks 0 and 3 to be increased to 1.8 gm/m² if tolerated, given IV infusion over 2 hours with MESNA and fluids.
**Time of re-evaluation (at weeks 12, 24, and 40 end of therapy).